Industry
Biotechnology
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Loading...
Open
5.14
Mkt cap
155M
Volume
416K
High
5.15
P/E Ratio
-2.98
52-wk high
14.30
Low
4.83
Div yield
N/A
52-wk low
0.77
Portfolio Pulse from
November 09, 2024 | 3:30 pm
Portfolio Pulse from
November 05, 2024 | 3:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 1:02 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:05 pm
Portfolio Pulse from Michael Juliano
July 18, 2024 | 5:36 pm
Portfolio Pulse from Dylan Berman
June 13, 2024 | 3:52 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Insights
June 03, 2024 | 8:31 pm
Portfolio Pulse from ryanfaloona@benzinga.com
May 30, 2024 | 12:41 pm
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 12:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.